Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Inspirion Wealth Advisors LLC

Inspirion Wealth Advisors LLC grew its position in Edwards Lifesciences Co. (NYSE:EW) by 4.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,763 shares of the medical research company’s stock after buying an additional 488 shares during the period. Inspirion Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $853,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Prosperity Consulting Group LLC boosted its stake in shares of Edwards Lifesciences by 3.6% in the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock valued at $289,000 after purchasing an additional 134 shares during the period. Abacus Planning Group Inc. boosted its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after acquiring an additional 140 shares during the last quarter. Versant Capital Management Inc boosted its stake in Edwards Lifesciences by 9.3% during the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 145 shares during the last quarter. Kera Capital Partners Inc. boosted its stake in Edwards Lifesciences by 5.0% during the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 148 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after acquiring an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on EW shares. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, May 13th. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Citigroup reissued a “buy” rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a report on Friday, April 25th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average price target of $80.20.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $78.09 on Monday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $73.35 and a 200-day moving average of $72.50. The firm has a market cap of $45.81 billion, a price-to-earnings ratio of 11.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period last year, the company posted $0.66 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This represents a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This trade represents a 9.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,442 shares of company stock worth $4,025,799 over the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.